Evidence map›Paper›PMID 34791573›Full record

ArticleBrain tumor pathology2022

Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.

Shino Magaki, Radha Satyadev, Zesheng Chen, Kathryn S Yung, Harry V Vinters, Marsha C Kinney, Jonathan W Said

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Shino MagakiSection of Neuropathology, Department of Pathology and Laboratory Medicine, UCLA Medical Center and David Geffen School of Medicine, Los Angeles, CA, USA. smagaki@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-0433-5759
Radha SatyadevDepartment of Pathology, Kaiser Foundation Hospital, Anaheim, CA, USA.
Zesheng ChenSection of Neuropathology, Department of Pathology and Laboratory Medicine, UCLA Medical Center and David Geffen School of Medicine, Los Angeles, CA, USA.
Kathryn S YungDepartment of Radiology, Kaiser Permanente Irvine Medical Center, Irvine, CA, USA.
Harry V VintersSection of Neuropathology, Department of Pathology and Laboratory Medicine, UCLA Medical Center and David Geffen School of Medicine, Los Angeles, CA, USA.
Marsha C KinneyDivision of Hematopathology, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Jonathan W SaidDepartment of Pathology and Laboratory Medicine, UCLA Medical Center and David Geffen School of Medicine, Los Angeles, USA.
Ronald Reagan UCLA Medical Center · USKaiser Foundation Hospital · USKaiser Permanente Orange County Irvine Medical Center · USOlive View-UCLA Medical Center · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic large cell lymphomas (ALCL) are mature T-cell neoplasms, approximately half of which harbor rearrangements of the ALK gene that confer a good prognosis. Recent studies have demonstrated that a significant proportion of ALK-negative ALCLs demonstrate rearrangements of the IRF4/DUSP22 locus that also are typically associated with a favorable prognosis. ALCL with primary involvement of the central nervous system (CNS) is extremely rare. We report what may be the first case of ALK-negative ALCL with IRF4/DUSP22 rearrangement involving the brain in a 55-year-old man. Magnetic resonance imaging demonstrated signal abnormalities in the periventricular region, corpus callosum and cingulate gyrus. Biopsy revealed a diffuse parenchymal and angiocentric infiltrate of CD30-positive cells that showed IRF4/DUSP22 rearrangement by fluorescence in situ hybridization. We also review the clinical and pathologic features of primary CNS ALK-negative ALCLs in the literature and highlight the need for awareness of this entity to optimize appropriate management.

Indexed as

Lymphoma, Large-Cell, AnaplasticCentral Nervous SystemDual-Specificity PhosphatasesGene RearrangementHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedMitogen-Activated Protein Kinase PhosphatasesReceptor Protein-Tyrosine KinasesDual-Specificity PhosphatasesDUSP22 protein, humanMitogen-Activated Protein Kinase PhosphatasesReceptor Protein-Tyrosine KinasesALKAnaplastic large cell lymphomaCentral nervous systemIRF4/DUSP22

Identifiers

PMID34791573
PMCPMC8752532
OpenAlexW3211610920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.